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Objectives We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients.
Background When used in optimal doses to treat patients with heart failure, renin-angiotensin-aldosterone system (RAAS)
inhibitors improve clinical outcomes but can cause hyperkalemia.
Methods Participants in the CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity)
(n  7,599) Program were randomized to standard heart failure therapy plus candesartan or placebo, titrated as
tolerated to a target of 32 mg once daily with recommended monitoring of serum potassium and creatinine. We
assessed the incidence and predictors of hyperkalemia associated with dose reduction, study drug discontinua-
tion, hospitalization, or death over the median 3.2 years of follow-up.
Results Independent of treatment assignment, the risk of hyperkalemia increased with age 75 years, male gender,
diabetes, creatinine 2.0 mg/dl, K 5.0 mmol/l, and background use of angiotensin-converting enzyme inhib-
itors or spironolactone. Candesartan increased the rate of aggregate hyperkalemia from 1.8% to 5.2% (differ-
ence 3.4%, p  0.0001) and serious hyperkalemia (associated with death or hospitalization) from 1.1% to 1.8%
(difference 0.7%, p  0.001), with hyperkalemia associated with death reported in 2 (0.05%) candesartan pa-
tients and 1 (0.03%) placebo patient. The benefit of candesartan in reducing cardiovascular death or heart fail-
ure hospitalization (relative risk reduction 16%, p  0.0001) was uniform in these subgroups, as was the incre-
mental risk of hyperkalemia.
Conclusions The risk of hyperkalemia is increased in symptomatic heart failure patients with advanced age, male gender,
baseline hyperkalemia, renal failure, diabetes, or combined RAAS blockade. Although these groups derive incre-
mental clinical benefit from candesartan, careful surveillance of serum potassium and creatinine is particularly
important. (J Am Coll Cardiol 2007;50:1959–66) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.067b
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Hyperkalemia in the CHARM Program November 13, 2007:1959–66mellitus hampers baseline potas-
sium excretion. Moreover, opti-
mal medical therapy of patients
with symptomatic HF requires
simultaneous utilization of mul-
tiple neurohormonal antagonists
that alone and, especially, in
combination increase the risk of
hyperkalemia.
The CHARM (Candesartan in
Heart Failure-Assessment of Re-
duction in Mortality and Mor-
bidity) Program investigated the
impact of treatment with the an-
giotensin receptor blocker (ARB)
candesartan, both alone and in
combination with an ACE inhib-
itor, across a broad spectrum of
symptomatic HF patients, includ-
ing those with both depressed and
reserved left ventricular ejection fraction (LVEF) and those
reated with various combinations of neurohumoral antago-
ists. Protocol-directed, serial monitoring of serum potas-
ium and creatinine, as well as surveillance for serious
dverse events (including hyperkalemia) permitted a quan-
itative assessment of risk in both placebo- and candesartan-
ssigned patients. We utilized the CHARM Program to
nvestigate the incidence and predictors of hyperkalemia in
contemporary HF population managed with modern
edical therapy.
ethods
he CHARM Program. The design and overall results of
he CHARM Program have been previously reported in
etail (1). Eligible patients were women and men age 18
ears or older who had symptomatic HF (New York Heart
ssociation functional class II to IV) for at least 4 weeks’
uration. Major exclusion criteria included baseline serum
reatinine 3 mg/dl (265 mol/l); baseline serum potas-
ium 5.5 mmol/l (mEq/l); history of marked ACE
nhibitor-induced hyperkalemia resulting in either a serum
otassium 6.0 mmol/l or a life-threatening adverse event;
nown bilateral renal artery stenosis, symptomatic hypoten-
ion, critical aortic or mitral stenosis; recent (within 4
eeks) myocardial infarction, stroke, or open heart surgery;
nd use of an ARB within 2 weeks of trial enrollment.
ligible, consented patients were enrolled into 1 of 3 trials
ccording to LVEF higher than 40% (CHARM-Preserved,
 3,023), 40% or lower and treated with an ACE
nhibitor (CHARM-Added, n  2,548), or 40% or lower
nd not treated with an ACE inhibitor due to prior
ntolerance (CHARM-Alternative, n  2,028) (2–4). In
HARM-Added, investigators were instructed to use “in-
ividualized optimum doses” of ACE inhibitors based on
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
CI  confidence interval
CV  cardiovascular
eGFR  glomerular
filtration rate estimated by
the Modification of Diet in
Renal Disease method
HF  heart failure
LVEF  left ventricular
ejection fraction
OR  odds ratio
RAAS  renin-angiotensin-
aldosterone systemoses proven effective in clinical outcomes trials and indi- Hidual tolerability (2). Angiotensin-converting enzyme in-
ibitor use was left to the discretion of the investigator in
HARM-Preserved. The primary outcome for each of the
omponent trials was cardiovascular (CV) death or un-
lanned admission to the hospital for management of
orsening HF, which was also used as the primary outcome
or this supplementary, retrospective analysis. Whereas se-
um creatinine and potassium were measured on the full
ohort of 7,599 patients enrolled in CHARM-Overall, core
aboratory values were recorded only for the subset of 2,675
atients enrolled from North America.
Study drug was dosed according to an incremental,
iweekly, forced titration scheme. At randomization, study
rug was initiated at 4 mg once daily (or at 8 mg once daily
t the investigator’s discretion). The dose was then doubled
very 2 weeks as tolerated up to a maximum target dose of
2 mg candesartan (or matching placebo) once daily. Visits
ere scheduled at 2, 4, and 6 weeks; 6 months; and then
very 4 months until study end. Investigators were in-
tructed to assess serum creatinine and potassium before
rug initiation, within 2 weeks of dose escalation or com-
letion of dose titration, yearly thereafter, and at their
iscretion. There were no prespecified mandates regarding
he management of hyperkalemia. Follow-up was con-
ucted over a minimum of 2 years, and a maximum of 4
ears with median duration of 3.2 years.
For this analysis, the diagnosis of hyperkalemia was based
ot on a prespecified laboratory threshold, but on investi-
ator assessments of when clinically important increases in
erum potassium were present. Adverse events (serious or
onserious) that led to a dose reduction or discontinuation
f study drug treatment, including hyperkalemia, were
outinely reported on the case report forms. Narrative
ummaries of all hospitalization and death events in the
HARM Program were examined using a free text search
o identify those that were associated with hyperkalemia,
ithout regard to attribution of causality to treatment by the
nvestigators. A post-hoc composite outcome of “clinically
mportant hyperkalemia” was then defined to identify all
yperkalemia events requiring medical intervention, includ-
ng hyperkalemia requiring study drug dose reduction, study
rug discontinuation, or hospitalization or hyperkalemia
ausing death. This composite outcome was designed to
eflect a more all-encompassing “worst-case” scenario defi-
ition for hyperkalemia in the absence of an effective
onitoring strategy, making the conservative assumption
hat all dose reductions or discontinuations would have
ecome serious events (hospitalization or death) had they
ot occurred.
tatistics. We determined the incidence of clinically im-
ortant hyperkalemia for both placebo- and candesartan-
reated patients in CHARM-Overall and in each of the
omponent CHARM trials. Odds ratios (ORs) and 95%
onfidence intervals (CIs) comparing treatments, stratified
y trial and by subgroups, were derived using the Mantel-
aenszel method. Incidence rates (per 1,000 patient-years)
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November 13, 2007:1959–66 Hyperkalemia in the CHARM Programere also calculated to account for variable exposure dura-
ion across the different CHARM trials. The composite
yperkalemia outcome and the clinical efficacy outcome of
V death or HF hospitalization were examined in sub-
roups according to baseline demographic factors and clin-
cal features previously reported to increase risk for hyper-
alemia (5) (age 75 years, male gender, diabetes,
oncurrent ACE inhibitor or spironolactone use, baseline
reatinine 2.0 mg/dl, and baseline potassium 5.0 mmol/l),
sing a test for heterogeneity to assess for interactions between
ubgroup and treatment assignment. As baseline values of
reatinine and potassium were available from the case report
orms only for patients enrolled in North America, the
nalysis for these subgroups was confined to the North
merican study population. The time to development of
linically important hyperkalemia (and serious hyperkale-
ia) was analyzed using Cox proportional hazards models
nd displayed in standard Kaplan-Meier plots. Finally, Cox
odels including age 75 years, male gender, diabetes,
CE inhibitor or spironolactone use, and treatment assign-
ent were utilized to examine the multivariate predictors of
linically important hyperkalemia. Models were extended to
nclude baseline potassium and renal function (measured as
oth serum creatinine and as glomerular filtration rate
stimated by the Modification of Diet in Renal Disease
ethod [eGFR] [6]) in the subset of patients for whom
aboratory data were available. All analyses were conducted
sing SAS statistical software (Cary, North Carolina).
reakdown of Hyperkalemia Outcomes in CHARM-Overall
Table 1 Breakdown of Hyperkalemia Outcomes in CHARM-Over
Outcome
Overall
n/N (%)
Per 1,000
Patient-yrs
Study drug dose reduction for
hyperkalemia
77/7,599 (1.0%) 3.6 17/3,
Study drug discontinuation for
hyperkalemia
115/7,599 (1.5%) 5.4 22/3,
Hospitalization or death
associated with hyperkalemia
110/7,599 (1.4%) 5.1 40/3,
Death associated with
hyperkalemia
3/7,599 (0.04%) — 1/3,
Clinically important hyperkalemia
(at least 1 of the above)
267/7,599 (3.5%) 12.6 70/3,
ote that outcomes are not mutually exclusive, so row totals cannot be added.
CI  confidence interval; OR  odds ratio.
linically Important Hyperkalemia in CHARM
Table 2 Clinically Important Hyperkalemia in CHARM
Trial
Overall
n/N (%)
Per 1,000
Patient-yrs n/N (%)
CHARM-Alternative 55/2,028 (2.7%) 10.6 15/1,015 (1
CHARM-Added 144/2,548 (5.7%) 19.6 37/1,272 (2
CHARM-Preserved 68/3,023 (2.3%) 7.8 18/1,509 (1
CHARM-Overall 267/7,599 (3.5%) 12.6 70/3,796 (1s noted in the text, hyperkalemia is defined as fatal hyperkalemia or hyperkalemia requiring dose redu
Abbreviations as in Table 1.esults
he breakdown of adverse events associated with hyperka-
emia reported for the overall CHARM Program is dis-
layed in Table 1. Overall, clinically important hyperkale-
ia was noted in 1.8% of placebo-treated (6.6 events/1,000
atient-years) and 5.2% of candesartan-treated patients
18.5 events/1,000 patient-years) in CHARM-Overall, re-
ecting an excess absolute risk of 3.4% with candesartan
herapy (11.9 events/1,000 patient-years). The excess of
erious hyperkalemia events (hospitalization or death) was
.7% (1.8% vs. 1.1% for placebo), reflecting a difference of
.7 events/1,000 patient-years. Hyperkalemia associated
ith death was rare in the CHARM Program, and was
eported for only 3 (0.04%) patients in the overall program,
ncluding 2 (0.05%) patients assigned to candesartan in the
HARM-Added trial, and 1 patient (0.03%) assigned to
lacebo in the CHARM-Alternative study.
The incidence of clinically important hyperkalemia (here-
fter, hyperkalemia) according to treatment assigned in the
omposite CHARM Program and each of the component
rials is summarized in Table 2. Hyperkalemia was most
ommon for both placebo- and candesartan-treated patients
n CHARM-Added (2.9% placebo, 8.4% candesartan) in
hich patients were treated concurrently with an ACE
nhibitor (p  0.001). Candesartan increased the risk of
yperkalemia relative to placebo in each of the CHARM
omponent trials and in CHARM-Overall (OR 2.9, 95%
Placebo Candesartan
OR (95% CI))
Per 1,000
Patient-yrs n/N (%)
Per 1,000
Patient-yrs
.5%) 1.6 60/3,803 (1.6%) 5.5 3.6 (2.1–6.1)
.6%) 2.1 93/3,803 (2.5%) 8.6 4.3 (2.7–6.9)
.1%) 3.8 70/3,803 (1.8%) 6.5 1.7 (1.2–2.6)
.03%) — 2/3,803 (0.05%) — 2.0 (0.2–22.0)
.8%) 6.6 197/3,803 (5.2%) 18.5 2.9 (2.2–3.9)
bo Candesartan
OR (95% CI)
Per 1,000
Patient-yrs n/N (%)
Per 1,000
Patient-yrs
5.9 40/1,013 (4.0%) 15.4 2.7 (1.5–5.0)
10.1 107/1,276 (8.4%) 29.1 3.1 (2.1–4.5)
4.1 50/1,514 (3.3%) 11.5 2.8 (1.6–4.9)
6.6 197/3,803 (5.2%) 18.5 2.9 (2.2–3.9)all
n/N (%
796 (0
796 (0
796 (1
796 (0
796 (1Place
.5%)
.9%)
.2%)
.8%)ction, study drug discontinuation, or hospitalization.
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Hyperkalemia in the CHARM Program November 13, 2007:1959–66I 2.2 to 3.9), but there was no heterogeneity in the
ncremental risk of hyperkalemia with candesartan across
he different trial populations (p for interaction by study 
.95). Hyperkalemia was, however, more common in the
ow LVEF patients as a whole (CHARM-Added 
HARM-Alternative) than in those with preserved LVEF
CHARM-Preserved) (4.3% vs. 2.3%, p  0.001).
atient subgroups at high risk for hyperkalemia in
HARM-Overall. Independent of treatment assignment
n the CHARM-Overall study, the risk of hyperkalemia
ncreased with male gender, age 75 years, diabetes, back-
round use of ACE inhibitors or spironolactone, baseline
reatinine 2.0 mg/dl, and baseline potassium 5.0
mol/l (Table 3). The greatest relative risk increase for
yperkalemia was seen in those with baseline renal insuffi-
iency, whether or not they received candesartan (OR 
.1, 95% CI 2.4 to 7.3 for creatinine 2.0 vs. 2.0 mg/dl).
erious hyperkalemia events (associated with hospitalization
r death) were also more common in this group (OR  3.5,
5% CI 1.5 to 7.9 for creatinine 2.0 vs. 2.0 mg/dl).
otably, the incidence of hyperkalemia in patients with
reatinine2 mg/dl receiving placebo (10%) was more than
wice that of patients with creatinine 2 mg/dl receiving
andesartan (4.9%).
The incremental risk of hyperkalemia with candesartan
herapy (roughly 3-fold) over placebo was statistically
niform in each of the examined subgroups (p for interac-
Clinically Important Hyperkalemia by Subgroups
Table 3 Clinically Important Hyperkalemia b
Clinically Important
Hyperkalemia
n/N (%)
Rate
(Per 1
Overall CHARM 267/7,599 (3.6%)
Age
75 yrs 75/1,736 (4.3%)
75 yrs 192/5,863 (3.3%)
Male gender
Yes 203/5,199 (3.9%)
No 64/2,400 (2.7%)
History of diabetes
Yes 117/2,163 (5.4%)
No 150/5,436 (2.8%)
On ACE inhibitor
Yes 166/3,125 (5.3%)
No 101/4,474 (2.3%)
On spironolactone
Yes 71/1,271 (5.6%)
No 196/6,327 (3.1%)
Baseline creatinine
2.0 mg/dl 21/154 (13.6%)
2.0 mg/dl 92/2,521 (3.8%)
Baseline potassium
5.0 mEq/l 30/260 (11.5%)
5.0 mEq/l 82/2,410 (3.4%)
Baseline serum creatinine and potassium were available only for pati
ACE  angiotensin-converting enzyme; other abbreviations as in Taion 0.10) (Fig. 1) excepting those on spironolactone, for ahom the odds of hyperkalemia with candesartan appeared
o be substantially higher (p for interaction  0.04). In
ultivariable Cox models containing treatment assignment,
ge 75 years, gender, blood pressure, diabetes, ACE
nhibitor use, spironolactone use, nonsteroidal anti-
nflammatory drug use, ejection fraction 40%, beta-
locker use, and loop diuretic use, assignment to candesar-
an, male gender, age 75 years, diabetes, and background
se of ACE inhibitors or spironolactone remained clinically
mportant predictors of hyperkalemia. The multivariable
azard ratios for hyperkalemia in the full CHARM cohort
re outlined in Table 4. When the model was extended to
nclude baseline creatinine and potassium for the subset of
,675 patients in whom laboratory data were available, the
ffects of gender and diabetes were attenuated, but renal
unction, baseline potassium, age 75 years, baseline use of
CE inhibitors or spironolactone, and assignment to can-
esartan were still relevant predictors. Of note, substituting
GFR (in quintiles) for creatinine as a measure of renal
unction improved the overall model fit and accounted for
ge, but did not change the other relevant multivariable
ssociations. Independent of treatment assignment, the risk
f hyperkalemia in the CHARM Program steadily in-
reased across eGFR quintiles with the greatest risk seen
n the group with eGFR 45 cc/min (corresponding
oughly to a creatinine of 2.0 mg/dl).
Despite increased risk, candesartan therapy was associ-
RM-Overall
groups, CHARM-Overall
erkalemia
Patient-yrs)
OR for Hyperkalemia
(95% CI)
p Value
(Subgroup)
.6 —
.0 1.3 (1.0–1.8) 0.049
.4
.0 1.4 (1.1–2.0) 0.007
.5
.5 2.0 (1.6–2.6) 0.001
.6
.8 2.4 (1.9–3.2) 0.001
.1
.8 1.8 (1.4–2.5) 0.001
.9
.2 4.1 (2.4–7.3) 0.001
.2
.5 3.7 (2.3–5.8) 0.001
.5
rolled in North America., CHA
y Sub
of Hyp
,000
12
17
11
14
9
20
9
18
8
21
10
61
13
43
12ted with a consistent, highly significant (p  0.0001) 16%
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November 13, 2007:1959–66 Hyperkalemia in the CHARM Programeduction in the primary end point of CV death or hospi-
alization for the management of HF across all subgroups
Fig. 2). Although the increased incidence of hyperkalemia
elated to candesartan appeared to be higher during the first
to 6 months (while drug titration was occurring and
uring which serum potassium values were being checked
ore frequently), hyperkalemia events (including serious
Figure 1 Impact of Candesartan on Hyperkalemia Risk in CHAR
Subgroups assigned according to patient characteristics at baseline. Baseline valu
enrolled in North America. ACE  angiotensin-converting enzyme.
ultivariable HRs forlinically Important Hyperkalemia
Table 4 Multivariable HRs forClinically Important Hyperkalemia
Parameter HR (95% CI)
Multivariable model excluding potassium and
creatinine (full CHARM cohort, n  7,599)
Treatment assignment 2.8 (2.2–3.7)
Age >75 yrs 1.7 (1.3–2.3)
Diabetes 2.0 (1.6–2.6)
ACE inhibitor use 1.8 (1.1–3.1)
Spironolactone use 1.8 (1.3–2.3)
Male gender 1.4 (1.0–2.0)
Multivariable model including potassium and
creatinine (North American cohort, n  2,675)
Treatment assignment 2.1 (1.4–3.1)
Age >75 yrs 1.5 (1.0–2.3)
Diabetes 1.2 (0.8–1.7)
ACE inhibitor use 2.2 (1.0–4.6)
Spironolactone use 1.6 (1.0–2.4)
Male gender 1.3 (0.8–1.9)
Creatinine >2.0 3.4 (2.1–5.7)
Potassium >5.0 2.6 (1.7–4.0)
wo models are shown: one for the full CHARM cohort (n  7,599) excluding baseline serum
reatinine and potassium and one for the North American cohort (n  2,675) in whom baseline
erum and creatinine were available. Estimates for both models are derived from Cox proportional
azards regression adjusted for the variables listed as well as ejection fraction (40% vs. 40%),
ystolic blood pressure, beta-blocker use at baseline, nonsteroidal anti-inflammatory drug use at1
aseline, and loop diuretic use at baseline. Variables in bold were significant at the p 0.05 level.
ACE  angiotensin-converting enzyme; HR  hazard ratio; other abbreviations as in Table 1.vents associated with hospitalization or death) accrued over
he entire study period (Fig. 3). The overall, unadjusted
azard ratio for hyperkalemia with candesartan therapy was
.8 (95% CI 2.1 to 3.7, p  0.0001), and the hazard ratio
or serious hyperkalemia events (hospitalization or death)
as 1.7 (95% CI 1.2 to 2.5, p  0.006).
iscussion
ur analysis of the CHARM Program demonstrates that
linically important hyperkalemia occurred in a broad spectrum
f symptomatic HF patients, whether or not they were treated
ith candesartan. Hyperkalemia events accrued throughout
he study period, not merely during the dose titration phase of
he study. Relative to placebo, candesartan therapy was
ssociated with 34 excess hyperkalemia events per 1,000
atients over a median 3.2 years of follow-up (11.9 events/
,000 patient-years). By comparison, candesartan treatment
as associated with 43 fewer CV death or HF hospitaliza-
ion events per 1,000 patients (23 events/1,000 patient-
ears) in the CHARM-Overall study, as well as numerical
eductions in all-cause (approximately 16 fewer events/
,000 patients) and CV mortality (approximately 21 fewer
vents/1,000 patients) (1). Due to an effective, protocol-
irected monitoring strategy and the conduct of this study at
ites committed to the care of patients in the context of a
linical trial, many hyperkalemia events prompted a dose
hange or study drug discontinuation without important
onsequence for the patient. Serious hyperkalemia events,
owever, remained more common in candesartan-treated
atients, with an excess of 7 hyperkalemia-associated hos-
italization or death events per 1,000 patients (2.7 events/
erall, by Subgroups
serum potassium and creatinine were available only for the subset of patientsM-Ov
es for,000 patient-years) over the follow-up period and an
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Hyperkalemia in the CHARM Program November 13, 2007:1959–66pparent excess of only 1 hyperkalemia-associated death in
he 3,803 patients treated with candesartan.
Subgroups at highest risk for hyperkalemia in the
HARM Program were those with advanced age, diabetes,
ale gender, high potassium at baseline, renal dysfunction
identified by creatinine 2 mg/dl or eGFR 45 cc/min/
.73 m2), and those receiving background therapy with
CE inhibitors or spironolactone. After adjusting for base-
ine potassium and renal function in multivariable models
for the subset of patients in whom data were available), the
ddition of candesartan to standard medical therapy for HF
Figure 2 Impact of Candesartan on CV Death or HF Hospitaliza
Subgroups are identical to those in Figure 1. CV  cardiovascular; HF  heart fail
Figure 3 Cumulative Incidence of Significant
Hyperkalemia, CHARM-Overall
Solid lines represent candesartan-treated patients and dashed lines represent
placebo-treated patients. “Any Hyperkalemia” (black) indicates hyperkalemia
associated with dose reduction, dose discontinuation, hospitalization, or death.
“Serious Hyperkalemia” (red) refers only to those hyperkalemia events associ-
ated with hospitalization or death. HR  hazard ratio (95% confidence interval).eas associated with 2- to 3-fold increase in risk that was
urther amplified by cotreatment with ACE inhibitors or
pironolactone. Combination RAAS blockade, therefore,
hould provoke special concern for hyperkalemia among
linicians, especially on the backdrop of renal dysfunction.
The ability of the kidney to maintain potassium ho-
eostasis is critically dependent on adequate renal perfusion
nd sodium delivery to the distal nephron, normal aldoste-
one production, and normal function of aldosterone-
ensitive potassium channels in the cortical collecting duct.
ncreases in dietary potassium load (e.g., through potassium
upplementation), reduction in the filtered sodium load (as
consequence of intrinsic renal disease, nephrotoxins, hypo-
olemia, or reduced cardiac output), diminished aldosterone
roduction (as a result of old age, diabetes, or drugs that inhibit
enin release), or attenuated tissue responsiveness to aldoste-
one or decreased skeletal muscle uptake of potassium (as a
onsequence of aldosterone-blockade or beta-2 receptor block-
de) may therefore precipitate hyperkalemia in the vulnerable
atient. Since aldosterone production is decreased in the
lderly, patients with diabetes, and in patients receiving drugs
hat block the production or action of renin (nonsteroidal
nti-inflammatory drugs, renin inhibitors including beta-
lockers) and angiotensin II (ACE inhibitors and ARBs),
hese groups are particularly vulnerable to the development of
yperkalemia with additional perturbations of potassium ho-
eostasis. Progressive decline in glomerular filtration rate as a
onsequence of age-related nephron loss and comorbid medi-
al illness further enhances the risk of hyperkalemia.
Hyperkalemia is a well-known complication of medical
herapy for symptomatic HF (7). When used in optimal
oses, several inhibitors of the RAAS reduce morbidity and
ortality in this population, but also reduce potassium
by Subgroups, CHARM-Overall
her abbreviations as in Figure 1.tion,
ure; otxcretion, especially in those with pre-existing renal dys-
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November 13, 2007:1959–66 Hyperkalemia in the CHARM Programunction (8). Fortunately, increases in serum potassium are
ypically modest (1 mEq/l), and severe or life-threatening
yperkalemia is uncommon (9). Increasingly, however, op-
imal medical therapy for patients with HF due to systolic
ysfunction relies heavily on simultaneous treatment with
ultiple neurohormonal antagonists that collectively am-
lify the risk of significant hyperkalemia when used in
ffective doses, particularly in patients with diabetes or
nderlying renal disease.
Enhanced prescription of spironolactone, an aldosterone
eceptor antagonist, spurred by the results of the landmark
ALES (Randomized Aldactone Treatment Evaluation
tudy) (10), was associated with a dramatic increase in the
ates of hospitalization for hyperkalemia in a recently
ublished large, community-based sample (11). This expe-
ience highlights the potential difference between the care-
ully controlled environment of a clinical trial and the
roader application of new therapies to a “real world”
opulation (12). Although an excess of serious hyperkalemia
vents was observed in 2.7 per 1,000 patient-years in
HARM, the number may have been as high as 11.9 per
,000 patient-years had an effective monitoring strategy not
een in place. However, even this more all-encompassing
worst-case scenario” of hyperkalemia in the CHARM
rogram likely underestimates the incidence in an un-
elected population of patients with HF in the community
ho may be more vulnerable due to age, comorbid medical
llness (particularly renal failure), and less careful monitor-
ng than that offered in the context of a clinical trial.
uttressing this concern, it has been observed that moni-
oring for hyperkalemia in patients treated with RAAS
lockade remains poor, with nearly 30% to 60% of patients
ailing to receive recommended surveillance of serum potas-
ium (13,14). Nonetheless, the increased risk of hyperkale-
ia associated with candesartan (and, presumably, other
RB) therapy in HF must be interpreted in the context of
ts clear benefits with regard to CV morbidity and mortality,
ven among populations at special risk for elevated potas-
ium (15,16), and as well in the context of potentially
educed serious adverse events related to hypokalemia (0.4%
n candesartan-treated patients versus 0.9% in placebo-
reated patients in the CHARM Program).
Our analysis must be viewed with attention to its limita-
ions. This was a retrospective analysis using a post-hoc
efinition of “clinically important hyperkalemia.” The deci-
ion to report an adverse event of hyperkalemia and the
anagement of hyperkalemic patients were left to the
iscretion of the individual investigators; as such, the actual
erum potassium values and clinical context (such as elec-
rocardiographic manifestations) at the time of adverse
vents were not available for analysis. Although guidelines
or monitoring of serum potassium were provided to the
HARM investigators (particularly during dose titration),
o regularly scheduled surveillance of serum potassium was
andated. It is possible therefore, that physicians may haventervened to manage potassium levels that would have been Zell tolerated by the patients, or alternatively, that hyper-
alemia may have gone undetected because it was not
ssociated with specific electrocardiographic or clinical
anifestations. Finally, though hyperkalemia prompting
tudy drug dose reduction or discontinuation was specifi-
ally reported in the case report forms for the trial, hospi-
alization or death associated with hyperkalemia was only
dentifiable from review of investigator-reported adverse
vents. Although we may as a consequence have included
ome hospitalizations that were not specifically due to
yperkalemia, we believe that our conservative assumption
eflects the upper bound of the incidence of clinically
mportant hyperkalemia in the CHARM study.
Additional studies of hyperkalemia in large community
ohorts or registries are necessary to more accurately mea-
ure the incidence outside the context of a clinical trial. In
he absence of such data, however, our data from the
HARM Program provide important reference points for
racticing clinicians to gauge the risk for hyperkalemia in
he management of patients with HF. Reassuringly, many
yperkalemia events in the CHARM Program could be
dequately addressed by dose adjustment or discontinuation
f the study drug, with the minority progressing to hospi-
alization or death. We conclude that periodic surveillance
f serum potassium and creatinine (e.g., at baseline, within
to 2 weeks of a change in drug dosing, and at least
nnually thereafter) is critically important to limiting ad-
erse events. The subset of older HF patients who have
oderate or severe renal dysfunction (stage III chronic
idney disease or worse, many of whom were not eligible for
he CHARM Program), those with high serum potassium
t baseline, and those who receive combination RAAS
ntagonists are particularly vulnerable, necessitating even
loser monitoring. As well, in all patients with HF, strate-
ies to limit the toxicity of RAAS antagonists, such as
estriction of potassium supplements (and in some cases,
ietary potassium), elimination of drugs that may impair
enal potassium excretion (e.g., nonsteroidal anti-
nflammatory drugs, herbal remedies, licorice), and careful
ssessment of baseline renal function to identify those at
specially high risk (e.g., eGFR 45 cc/min/1.73 m2),
hould be routinely considered (17). The addition of can-
esartan to standard HF therapy should be undertaken
autiously, if at all, where adequate monitoring of potassium
nd renal function is not possible. Although candesartan
rovides important incremental benefits with regard to CV
orbidity and mortality over standard medical therapy for
F, a favorable balance of benefit and risk requires clinical
igilance and regular laboratory surveillance, particularly
mong patients at high baseline risk for hyperkalemia.
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